Sustainability Matters: Carbon Neutral | Boehringer Ingelheim US
Find out more on how Boehringer Ingelheim are going carbon neutral at our manufacturing plant in Gainesville, Georgia, embracing sustainability.
Search
Transition to renewable energy signals a broader commitment to environmental sustainability
Transition to renewable energy signals a broader commitment to environmental sustainability
Ways we’re protecting the planet
Click here to read a few examples of the sustainability practices we’ve put in place at our U.S. HQ, to protect the planet for a more sustainable tomorrow.
Building lasting partnerships for a better future
Working with the University of Georgia, we’ve co-created a sustainability training initiative that benefits people, animals and the planet.
BI increases commitments to sustainable development
At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development
Animal Health: Our Responsibility
BI's commitment to animal health is reflected in our more than 100 years of successful company history. It is also at the core of sustainability.
Sustainable Development for Generations | Boehringer Ingelheim US
At BI, Sustainable Development – For Generations is about a journey. One that started in 1885 and one that we hope, and believe, will never end.
Biosimilars
Biosimilars
Bigger Role in Ensuring Food Security | Boehringer Ingelheim US
As the population of the earth grows, animal health becomes fundamental in ensuring well-being and the global protein supply. Click here to find out more.
More Health Overview
Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.
Advancing green chemistry for more sustainable medicines
By applying the principles of eco-design and green chemistry, we developed an innovative manufacturing process with reduced environmental footprint.
Biosimilars
: A biosimilar is a version of a biologic medication that is made by a different company than the one that invented it, with no clinically meaningful differences in terms of safety, potency and purity.
Sustainable cattle production: Feeding the world while minimizing environmental effect
Sustainable cattle production: Feeding the world while minimizing environmental effect
Partnering Culture
BI's long-term research and investment focus means we can work together to realize their ideas by fully committing to lasting relationships.
Parasiticides
Parasiticides
Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial
Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial
Simon Manyara
Simon Manhara works with our culture and sustainability team towards making a positive social impact and creating a sustainable future.
Edda Dankmeyer
Edda Dankmeyer leads Sustainable Development Communications and explains how sustainable development can bea key differentiator for the company.
Transboundary and Emerging Diseases | Boehringer Ingelheim US
Click here to find out more on how Boehringer Ingelheim fights transboundary and emerging diseases through cutting-edge technologies.
FDA approved treatment option for adults with CKD
The FDA has approved Jardiance® (empagliflozin) tablets to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death and hospitalization in adults with CKD at risk of progression.
More Potential
More Potential
Corporate Profile
Corporate Profile
About Us
Click here to discover more about Boehringer Ingelheim and our headquarters and largest U.S subsidiary in Connecticut.
Purchasing
Suppliers are an integral part of our success. We are passionate about solutions and new opportunities to review, improve and optimize our supplier base.
New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF
New Data Shows OFEV® (nintedanib) Efficacy is Sustained Long-term with No New Safety Signals in Patients with IPF